KRAS and lung adenocarcinoma: In studies by Chaft et al. (2012) and Scheffler et al. (2015), it was concluded that PIK3CA mutations in lung adenocarcinomas typically occur simultaneously with EGFR, KRAS, and ALK mutations [2,27].